Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

lortalamine × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1 Disease 1

Interventions

Docetaxel 408 pembrolizumab 330 Prednisone 289 enzalutamide 281 Gemcitabine 271 Radiotherapy 269 Magnetic Resonance Spectroscopy 266 Nivolumab 252 Abiraterone Acetate 217 Cisplatin 210 Leuprolide 195 Radiosurgery 191 Sunitinib 188 Carboplatin 162 Androgen Antagonists 153 bicalutamide 150 Goserelin 149 Specimen Handling 147 Ipilimumab 130 Paclitaxel 127 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122 apalutamide 117 Cyclophosphamide 117 Bevacizumab 116 Sorafenib 114 Everolimus 111 cabozantinib 104 atezolizumab 104 abiraterone 104 Biopsy 101

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02615067 2019-04-10

proSPECT-AS

Molecular Insight Pharmaceuticals, Inc.

Phase 3 Completed

Disease, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡